Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 3
2005 1
2006 2
2007 1
2008 2
2009 4
2010 3
2011 2
2012 2
2013 3
2014 7
2015 6
2016 6
2017 3
2018 6
2019 8
2020 5
2021 5
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.
Adam-Artigues A, Arenas EJ, Martínez-Sabadell A, Brasó-Maristany F, Cervera R, Tormo E, Hernando C, Martínez MT, Carbonell-Asins J, Simón S, Poveda J, Moragón S, Zazo S, Martínez D, Rovira A, Burgués O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo JM. Adam-Artigues A, et al. Among authors: rovira a. Sci Adv. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. Epub 2022 May 20. Sci Adv. 2022. PMID: 35594351 Free PMC article.
Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors.
Yélamos J, Galindo M, Navarro J, Albanell J, Rovira A, Rojo F, Oliver J. Yélamos J, et al. Among authors: rovira a. Oncoimmunology. 2015 Jul 1;5(1):e1065370. doi: 10.1080/2162402X.2015.1065370. eCollection 2016. Oncoimmunology. 2015. PMID: 26942084 Free PMC article. Review.
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.
Cabello P, Torres-Ruiz S, Adam-Artigues A, Forés-Martos J, Martínez MT, Hernando C, Zazo S, Madoz-Gúrpide J, Rovira A, Burgués O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo JM, Eroles P. Cabello P, et al. Among authors: rovira a. Cancers (Basel). 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. Cancers (Basel). 2023. PMID: 37046799 Free PMC article.
Targeted therapies in breast cancer.
Rojo F, Albanell J, Rovira A, Corominas JM, Manzarbeitia F. Rojo F, et al. Among authors: rovira a. Semin Diagn Pathol. 2008 Nov;25(4):245-61. doi: 10.1053/j.semdp.2008.08.001. Semin Diagn Pathol. 2008. PMID: 19013891 Review.
Genetic changes in small cell lung carcinoma.
Arriola E, Cañadas I, Arumí M, Rojo F, Rovira A, Albanell J. Arriola E, et al. Among authors: rovira a. Clin Transl Oncol. 2008 Apr;10(4):189-97. doi: 10.1007/s12094-008-0181-1. Clin Transl Oncol. 2008. PMID: 18411191 Review.
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
Casadevall D, Hernández-Prat A, García-Alonso S, Arpí-Llucià O, Menéndez S, Qin M, Guardia C, Morancho B, Sánchez-Martín FJ, Zazo S, Gavilán E, Sabbaghi MA, Eroles P, Cejalvo JM, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Casadevall D, et al. Among authors: rovira a. Mol Cancer Res. 2022 Jul 6;20(7):1108-1121. doi: 10.1158/1541-7786.MCR-21-0545. Mol Cancer Res. 2022. PMID: 35348729
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.
Santana-Hernández S, Suarez-Olmos J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera-Bel J, Menendez S, Arpí O, Bermejo B, Martínez MT, Cejalvo JM, Comino-Méndez I, Pascual J, Alba E, López-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A. Santana-Hernández S, et al. Among authors: rovira a. J Exp Clin Cancer Res. 2024 Jan 3;43(1):10. doi: 10.1186/s13046-023-02918-4. J Exp Clin Cancer Res. 2024. PMID: 38167224 Free PMC article.
71 results